<unk>  is or has been used in the treatment of hypogonadism, delayed puberty, and anemia in males and the treatment of breast cancer in women. It is specifically approved in one or more countries for the treatment of hypogonadism in men, delayed puberty in boys, and breast cancer in women. Current prescribing guidelines in the United States list only the treatment of androgen deficiency in males and breast cancer in females as indications.<unk>  is less effective in inducing masculinization than testosterone, but is useful for maintaining established masculinization in adults. Available forms<unk>  is available in the form of 2, 5, and 10 mg oral tablets.
Fluoxymesterone
Aminoglutethimide
Ethinylestradiol sulfonate
Hydroxyestrone diacetate
Ethisterone
Ethinylestradiol sulfate
Formestane
Retroprogesterone